Compare GWH & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GWH | KTTA |
|---|---|---|
| Founded | 2011 | 2020 |
| Country | United States | United States |
| Employees | 62 | 5 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9M | 23.2M |
| IPO Year | N/A | N/A |
| Metric | GWH | KTTA |
|---|---|---|
| Price | $1.02 | $0.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $2.25 | ★ $3.00 |
| AVG Volume (30 Days) | ★ 680.4K | 351.8K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $33.99 | N/A |
| Revenue Next Year | $1,328.57 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.74 | $0.28 |
| 52 Week High | $13.87 | $2.06 |
| Indicator | GWH | KTTA |
|---|---|---|
| Relative Strength Index (RSI) | 49.83 | 42.82 |
| Support Level | $0.74 | $0.68 |
| Resistance Level | $1.22 | $0.81 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 74.61 | 35.09 |
ESS Tech Inc is a long-duration energy storage company specializing in iron flow battery technology. It develops and manufactures long-duration energy storage systems based on iron flow battery technology. The company's batteries use earth-abundant materials, including iron, salt, and water, and are designed for high cycle life and recyclability. It operates as a single business operating segment, which includes all activities related to the design, engineering, and manufacturing of the company's long duration energy storage products. The company's revenue is derived from the sale of its energy storage products and from service contracts.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.